• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Concerta

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Concerta

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Concerta is a central nervous system (CNS) stimulant approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Its active ingredient is methylphenidate, and it is available as an extended-release tablet in four tablet strengths (18mg, 27mg, 36mg or 54mg of methylphenidate HCL). Each tablet is designed to have a 12-hour duration of effect.

    ADHD has three characteristic symptoms: inattention, hyperactivity, and impulsiveness. Some patients display more symptoms of hyperactivity and impulsiveness, while others may display more symptoms of inattentiveness. Methylphenidate has been used to treat ADHD for more than 30 years, and helps increase attention and decrease impulsiveness and hyperactivity in ADHD patients.

    Clinical Results

    Concerta was demonstrated to be effective in the treatment of ADHD in three double-blind, active and placebo-controlled studies in 416 children 6 to 12 years-old. The studies compared Concerta given qd, methylphenidate given tid over 12 hours, and placebo treatment in two single-center, three-week crossover studies and in a multicenter, four-week parallel-group comparison. The primary comparison of interest in all three trials was Concerta versus placebo.

    Symptoms of ADHD were evaluated by community school teachers using the Inattention/Overactivity with Aggression (IOWA) Conners scale. Statistically significant reduction in the Inattention/Overactivity subscale versus placebo was shown consistently across all three controlled studies for Concerta qd. (from FDA Label)

    Side Effects

    Reported side effects of Concerta include (but are not limited to) the following:

    • Headache
    • Stomach pain
    • Sleeplessness
    • Decreased appetite

    Other side effects seen with methylphenidate include nausea, vomiting, dizziness, nervousness, tics, allergic reaction, increased blood pressure, and psychosis (abnormal thinking or hallucinations).

    Concerta is contraindicated in patients with marked anxiety or agitation, glaucoma, or tics. It is also contraindicated during any treatment with monoamine oxidase inhibitors.

    Mechanism of Action

    Concerta uses osmotic pressure to deliver methylphenidate HCl at a controlled rate. The system, which resembles a conventional tablet in appearance, consists of an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat.

    The mode of methylphenidate HCl's therapeutic action in ADHD is not known. Methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Methylphenidate is a racemic mixture comprised of the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer. (from FDA Label)

    Additional Information

    For additional information, please visit the web site of Children and Adults with Attention-Deficit/Hyperactivity Disorder. This national, non-profit organization offers fact sheets and other sources of information on ADHD.

    Approval Date: 2000-08-01
    Company Name: Alza
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing